{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:07:47Z","timestamp":1750219667755,"version":"3.41.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.amjms.2025.04.008","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T23:21:48Z","timestamp":1744932108000},"page":"100-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The potential role of SGLT2 inhibitors in the management of amyloidosis"],"prefix":"10.1016","volume":"370","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-1323","authenticated-orcid":false,"given":"B\u00fclent","family":"\u00d6zlek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2025.04.008_bib0001","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejim.2022.05.013","article-title":"Impact of cardiac amyloidosis on outcomes of patients hospitalized with heart failure","volume":"102","author":"G\u00f6bel","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"16","key":"10.1016\/j.amjms.2025.04.008_bib0002","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.amjms.2025.04.008_bib0003","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjms.2025.04.008_bib0004","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-024-02294-z","article-title":"Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure","volume":"23","author":"Wang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"25","key":"10.1016\/j.amjms.2025.04.008_bib0005","first-page":"S0002","article-title":"Sodium glucose cotransporter 2 inhibitors in patients with amyloidosis with or without heart failure","author":"Augusto","year":"2025","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.amjms.2025.04.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101405","article-title":"Sodium-glucose cotransporter 2 inhibitor use and outcomes in transthyretin amyloid cardiomyopathy","volume":"3","author":"Jaiswal","year":"2024","journal-title":"JACC Adv"},{"issue":"24","key":"10.1016\/j.amjms.2025.04.008_bib0007","first-page":"S1547","article-title":"Impact of SGLT2 inhibitors on the outcomes of patients with cardiac arrhythmias and transthyretin cardiac amyloidosis","author":"Sivamurugan","year":"2024","journal-title":"Heart Rhythm"},{"issue":"24","key":"10.1016\/j.amjms.2025.04.008_bib0008","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 Inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjms.2025.04.008_bib0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.amjcard.2025.01.012","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in transthyretin amyloid cardiomyopathy","volume":"243","author":"Byer","year":"2025","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.amjms.2025.04.008_bib0010","article-title":"The role of sodium-glucose cotransporter-2 inhibitors in adults with transthyretin cardiac amyloidosis: a single-center retrospective cohort study","volume":"16","author":"Pillai","year":"2024","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.amjms.2025.04.008_bib0011","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.cardfail.2024.06.009","article-title":"Safety and efficacy of SGLT2 inhibitors for amyloid light-chain cardiomyopathy","volume":"30","author":"Lang","year":"2024","journal-title":"J Card Fail"},{"issue":"4","key":"10.1016\/j.amjms.2025.04.008_bib0012","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.amjms.2025.04.008_bib0013","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/jcm13010283","article-title":"Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis-A clinical feasibility study","volume":"13","author":"Steinhardt","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.amjms.2025.04.008_bib0014","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925009905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925009905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:43:20Z","timestamp":1750175000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962925009905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0002962925009905"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2025.04.008","relation":{},"ISSN":["0002-9629"],"issn-type":[{"type":"print","value":"0002-9629"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential role of SGLT2 inhibitors in the management of amyloidosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2025.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}